Inclusion Criteria:

- Histologically proven (biopsy or cytology) NSCLC (SCC, Adenocarcinoma, Large Cell)

- TNM clinical non-operable stage I/II and non-resectable stage IIIa/b without pleural
effusion

- Measurable disease

- No other malignancy, except non-melanomatous skin cancer, within 5 years prior to
participation in this study; the disease-free interval from any prior carcinoma must
be continuous

- Patient suitable for radical 3-DCRT

- ECOG-Performance status ≤ 2 / KPS > or equal to 60

- Weight loss <10% within the 3 months prior to diagnosis

- No prior radiotherapy to the thorax

- Patient is suitable for lung-board immobilisation

- No chemotherapy received prior to planning PET-CT scan

- Age 18 and over

- Provision of written informed consent

Exclusion Criteria:

- Evidence of any other significant clinical disorder or laboratory finding that makes
it undesirable for the patient to participate in the trial or if it is felt by the
research / medical team that the patient may not be able to comply with the protocol.

- FEV1 < 1